+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Global Insomnia Drug Pipeline Trends 2019: Discovery, Pre-clinical, Clinical, In Approval Therapeutics, Companies and Markets

  • ID: 4830036
  • Drug Pipelines
  • Region: Global
  • 101 pages
  • VPA Research
1 of 3

FEATURED COMPANIES

  • Eisai Co Ltd
  • Evotec AG
  • Imbrium Therapeutics LP
  • Janssen Pharmaceuticals
  • Leading BioSciences Inc
  • Merck & Co Inc
  • MORE
High levels of pipeline activity are being observed in Insomnia treatment during 2019. Clinical development activities are being undertaken by more than 25 companies including Alexza Pharmaceuticals Inc, Amherst Pharmaceuticals LLC, Blake Insomnia Therapeutics Inc, Cennerv Pharmaceuticals Ltd, Cosmas Therapeutics Development Inc and others.

A Significant contribution to the Insomnia pipeline is being observed from emerging companies opting for new approaches to clinical development strategy. The early stage and late-stage Insomnia pipeline included 26 compounds, driven by increasing number of targeted therapies. Progress is being made in accelerating compounds into advanced stages. However, fluctuating trends are being observed in average duration across three phases.

Increased understanding of underlying causes of Insomnia condition and increased access to investments is encouraging growth of Insomnia drug pipeline. However, despite high levels of pipeline activity, increasing clinical trial costs and decreasing drug approval rates is requiring companies to focus more on understanding clinical development pipeline compounds.

The research study is structured to provide clear and actionable insights into Insomnia drug pipeline for companies to optimize spending levels by understanding competition, their pipeline products and prospect of further advances over the next few years.

The report addresses the discovery, research and pre-clinical stage active Insomnia therapeutic candidates. Further, drugs in clinical stage including phase 1, phase 2, phase 3 and pre-registration phases are also analyzed.

The current report examines the current Insomnia pipeline along with current development status, regulatory progress, mechanism of action, route of administration, collaborating companies, sponsors, molecule type, and research/discovery details.

In addition to drug overview, recent developments, the report also provides mechanism of action, Pre-clinical trial details and Clinical trial details for each of the drug candidates of Insomnia. Further, orphan drug status, fast track designation, grants awarded and other special status for Insomnia pipeline compounds are also included.

This study was produced independently by the publisher from their proprietary databases, primarily to assist users to develop in-depth understanding of 2019 Insomnia pipeline and formulate effective research and development strategies.

Research Methodology

Our integrated data reports are built through robust research methodology to ensure our users can build on the insights and data accuracy for their expansion plans. Both primary and secondary research methods are used with stringent quality checks at each stage to evaluate trends, analysis and forecasts.

Scope of the Research

Insomnia Pipeline candidates
  • Pre-clinical Phase: Discovery, research, pre-clinical
  • Early Phase: Phase 1 and Phase 2 Insomnia drugs
  • Late phase: Phase 3 and in-approval Insomnia drugs
Companies involved in the Pipeline
  • Company overview
  • Snapshot
  • Insomnia therapeutic treatment activities
Details for each Insomnia drug candidate
  • Snapshot
  • Drug Name
  • Alternative Names
  • Company
  • Originator
  • Phase
  • Molecule Type
  • Orphan Drug Status
  • Drug Overview
  • Mechanism of Action
  • Current Status
  • Trial Details
Other details
  • Pre-clinical trials for each drug candidate
  • Clinical trials for each drug candidate
Recent Insomnia therapeutic candidates, clinical trials, investments, grants, partnerships, licenses, awards and other news
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • Eisai Co Ltd
  • Evotec AG
  • Imbrium Therapeutics LP
  • Janssen Pharmaceuticals
  • Leading BioSciences Inc
  • Merck & Co Inc
  • MORE
1.1 List of Tables
1.2 List of Figures

2 Executive Summary
2.1 Insomnia- Disease Overview
2.2 Insomnia- Pipeline Snapshot
2.3 Insomnia- Pipeline Drugs by Phase
2.4 Insomnia- Pipeline Drugs by Company
2.5 Insomnia- Pipeline Drugs by Mechanism of Action

3 Company wise Pipeline Analysis
3.1 Alexza Pharmaceuticals Inc Insomnia Drug Pipeline, H2- 2019
3.2 Amherst Pharmaceuticals LLC Insomnia Drug Pipeline, H2- 2019
3.3 Blake Insomnia Therapeutics Inc Insomnia Drug Pipeline, H2- 2019
3.4 Cennerv Pharmaceuticals Ltd Insomnia Drug Pipeline, H2- 2019
3.5 Cosmas Therapeutics Development Inc Insomnia Drug Pipeline, H2- 2019
3.6 Druggability Technologies Holdings Ltd Insomnia Drug Pipeline, H2- 2019
3.7 Eisai Co Ltd Insomnia Drug Pipeline, H2- 2019
3.8 Evotec AG Insomnia Drug Pipeline, H2- 2019
3.9 Grupo Ferrer Internacional SA Insomnia Drug Pipeline, H2- 2019
3.10 Idorsia Pharmaceutical Ltd Insomnia Drug Pipeline, H2- 2019
3.11 Imbrium Therapeutics LP Insomnia Drug Pipeline, H2- 2019
3.12 Intra-Cellular Therapies Inc Insomnia Drug Pipeline, H2- 2019
3.13 Janssen Pharmaceuticals Insomnia Drug Pipeline, H2- 2019
3.14 Leading BioSciences Inc Insomnia Drug Pipeline, H2- 2019
3.15 Linnet BioPharmaceuticals Inc Insomnia Drug Pipeline, H2- 2019
3.16 Merck & Co Inc Insomnia Drug Pipeline, H2- 2019
3.17 NB Health Laboratory Co Ltd Insomnia Drug Pipeline, H2- 2019
3.18 Neurim Pharmaceuticals Ltd Insomnia Drug Pipeline, H2- 2019
3.19 NeuroFix Therapeutics LLC Insomnia Drug Pipeline, H2- 2019
3.20 Overseas Pharmaceuticals Ltd Insomnia Drug Pipeline, H2- 2019
3.21 Reviva Pharmaceuticals Inc Insomnia Drug Pipeline, H2- 2019
3.22 Sage Therapeutics Inc Insomnia Drug Pipeline, H2- 2019
3.23 Shionogi & Co Ltd Insomnia Drug Pipeline, H2- 2019
3.24 Sosei Heptares Insomnia Drug Pipeline, H2- 2019
3.25 Taisho Pharmaceutical Holdings Co Ltd Insomnia Drug Pipeline, H2- 2019
3.26 Zelda Therapeutics Pty Ltd Insomnia Drug Pipeline, H2- 2019

4 Phase 1 Pipeline Drug Details
4.1 Insomnia- Phase 1 Drug Details
4.2 Insomnia- Phase 1 Drug Overview
4.3 Insomnia- Phase 1 Mechanism of Action
4.4 Current Status
4.5 Trial Details

5 Phase 2 Pipeline Drug Details
5.1 Insomnia- Phase 2 Drug Details
5.2 Insomnia- Phase 2 Drug Overview
5.3 Insomnia- Phase 2 Mechanism of Action
5.4 Current Status
5.5 Trial Details

6 Phase 3 Pipeline Drug Details
6.1 Insomnia- Phase 3 Drug Details
6.2 Insomnia- Phase 3 Drug Overview
6.3 Insomnia- Phase 3 Drug Mechanism of Action
6.4 Current Status
6.5 Trial Details

7 Pre-clinical Phase Pipeline Drug Details
7.1 Insomnia- Pre-clinical Phase Drug Details
7.2 Insomnia- Pre-clinical Phase Drug Overview
7.3 Insomnia- Pre-clinical Phase Drug Mechanism of Action
7.4 Current Status
7.5 Trial Details

8 Recent News and Developments

9 Appendix
9.1 About the Publisher
9.2 Sources and Research Methodology
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
  • Alexza Pharmaceuticals Inc
  • Amherst Pharmaceuticals LLC
  • Blake Insomnia Therapeutics Inc
  • Cennerv Pharmaceuticals Ltd
  • Cosmas Therapeutics Development Inc
  • Druggability Technologies Holdings Ltd
  • Eisai Co Ltd
  • Evotec AG
  • Grupo Ferrer Internacional SA
  • Sosei Heptares
  • Idorsia Pharmaceutical Ltd
  • Intra-Cellular Therapies Inc
  • Janssen Pharmaceuticals
  • Leading BioSciences Inc
  • Linnet BioPharmaceuticals Inc
  • Merck & Co Inc
  • NB Health Laboratory Co Ltd
  • Neurim Pharmaceuticals Ltd
  • NeuroFix Therapeutics LLC
  • Overseas Pharmaceuticals Ltd
  • Imbrium Therapeutics LP
  • Reviva Pharmaceuticals Inc
  • Sage Therapeutics Inc
  • Shionogi & Co Ltd
  • Taisho Pharmaceutical Holdings Co Ltd
  • Zelda Therapeutics Pty Ltd
Note: Product cover images may vary from those shown
Adroll
adroll